26th February 2024

The UK Antimicrobial Registry (UKAR) Study – a collaboration between BSAC and The University of Aberdeen – has now been open to participant recruitment for 9 months. During this time, hospitals from 22 NHS Trusts across Northern Ireland, Scotland, Wales and England have joined the UK-wide registry. In this short article, Kathleen and Azeezat, members of the NHS Grampian team, explain what it takes to be a successful site.

Teamwork

We are lucky to have nurse cover Monday to Friday to work on the UKAR Study. The communication within the team is open and non-judgmental, and we are happy to discuss any query we may have with the UKAR Study Office team.

Procedure

Our screening technique has developed through trial and error, and learning the best places to find our participants is an ongoing process. The introduction of the HEPMA system to our site has also made it easier to find out about prescriptions of the eligible study drugs.*

Determination   

As a team we are resilient and committed to achieving our goal. To begin with we found some aspects of the web-based database to be a bit challenging. We were involved in the pilot evaluation of the online case report form and have continued to work with the UKAR Study Office team to ensure effective data collection and upload.

Dissemination

Dr Noha El Sakka, Consultant and Service Clinical Director, Medical Microbiology and Virology and Principal Investigator (PI) of the UKAR Study at NHS Grampian has also been instrumental in making the study a success. Noha and members of the team have taken every opportunity to promote the study, speaking to Critical Care and Infectious Diseases colleagues during their departmental teaching sessions. Noha has also spread the word to potential Associate PIs, introducing the study during the 2023 National Infection Trainee Research Day in Edinburgh.

For more information about how your team can get involved, contact the UKAR team (ukar@abdn.ac.uk), visit the UKAR study website or complete the UKAR Expression of Interest Form.

11 UKAR eligible study drugs*

Cefiderocolǂ

Ceftaroline

Ceftazidime/avibactamǂ

Ceftobiprole

Ceftolozane/tazobactam

Dalbavancin

Delafloxacin

Eravacycline

Imipenem/cilastatin/relebactam

Meropenem/vaborbactam

Oritavancin

ǂAntimicrobial agents in the NICE de-linkage initiative.

GP? Pharmacist? Researcher? Social Scientist? Whatever field you work in, if you’re committed to fighting infection then we want you to join us as a BSAC Member.
Become a member

Having trouble finding what you're after?

Top